Browsing Tag
GSK plc
20 posts
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
GSK Q2 2026 core operating profit rises 7% on specialty medicines strength
GSK Q2 core operating profit rose 7% to £2.8bn, but a £1.3bn camlipixant hit and 2028-2030 dolutegravir cliff frame the £40bn 2031 sales delivery test.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
GSK Nuvalent acquisition puts $GSK in focus as $10.6bn oncology bet reshapes lung cancer pipeline
GSK is buying Nuvalent for USD 10.6bn to expand in lung cancer. Find out what the $GSK oncology deal means for investors.
Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?
Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
GSK wins China approval for Trelegy Ellipta in asthma, expanding respiratory market reach
Trelegy Ellipta is now approved for asthma in China, giving GSK dual coverage in COPD and asthma. Find out what this means for respiratory market dynamics.